Featured content
How AI-driven systems biology will reset the starting line for drug development
AI is making drug discovery faster, but can it make it more successful? Discover why combining AI with systems biology could help researchers tackle the biological complexity behind drug failure.
Article600+ patient-derived cancer models expand the search for drug targets
Hundreds of new patient-derived cancer models could strengthen target validation, identify cancer vulnerabilities and provide more representative systems for preclinical drug discovery.
ArticleWhy researchers are revisiting bisantrene decades after it was abandoned
An oncology drug abandoned decades ago is getting a second look, with new research uncovering a mechanism that could offer an alternative route to targeting MYC, one of cancer’s toughest targets.
ArticleTargeting childhood myopia progression with 7-methylxanthine
Childhood myopia researcher Dr Klaus Trier explores how 7-methylxanthine targets scleral remodelling and axial elongation, and its potential to slow disease progression and reduce the risk of high myopia.
News
NewsStem cell-grown kidney organoids could help uncover new treatments for AKI
Researchers at Monash University have grown miniature human kidneys from stem cells that could give drug discovery teams a more human-relevant model for investigating acute kidney injury and identifying therapies that promote tissue recovery.
NewsHER3-DXd and olaparib combination boosts lung cancer treatment responses
A new preclinical study finds that combining the antibody-drug conjugate HER3-DXd with PARP inhibitor olaparib significantly improves treatment responses in NSCLC models, including those harbouring EGFR and KRAS mutations, by overwhelming DNA repair capacity and activating innate immune signalling.
NewsFirst-in-class drug targets ‘undruggable’ MYC in blood cancers
A first-in-class experimental drug has demonstrated preclinical activity against treatment-resistant blood cancers by exploiting a newly identified vulnerability between MYC and GSPT1, offering a potential route to one of oncology’s most elusive targets.
NewsIL-17 identified as potential immunotherapy biomarker in ovarian cancer
A new study has identified IL-17 as a potential biomarker for immunotherapy response in a small subset of clear cell ovarian cancer cases, offering a possible route to personalised treatment for a disease historically resistant to immune-based therapies.
From our partners
Article
Antibody recycling, FcRn and the next generation of biologics
One receptor can protect antibodies from degradation, extend their half-life and become a drug target itself. Explore the science behind FcRn and how researchers measure its function.
Webinar
Oligonucleotide therapeutics safety considerations across drug development
As oligonucleotide therapeutics continue to advance, their safety assessment presents challenges that differ from traditional drug modalities. Discover how nonclinical safety studies, evolving regulatory expectations and real-world case examples can help you navigate these challenges with greater confidence.
Opinion and interviews
The global push to reduce animal testing in drug development
Non-animal methods are already used throughout early drug discovery, yet animal testing continues to dominate regulatory safety assessment. Recent initiatives suggest change is coming, but significant scientific and practical challenges remain.
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
Upcoming Webinars
Webinar
Meeting ethical & regulatory requirements when using human biological specimens
Whether you source, purchase or work with human biospecimens, understanding today’s ethical and regulatory expectations is essential. Join this webinar to explore informed consent, privacy and the principles that support responsible research.
Webinar
Building better therapeutic antibodies: the science, progress and problems to solve
As therapeutic antibodies become more complex, where is the field making real progress and which problems are proving hardest to solve? Hear leading experts share their perspectives.
Webinar
Oligonucleotide therapeutics safety considerations across drug development
As oligonucleotide therapeutics continue to advance, their safety assessment presents challenges that differ from traditional drug modalities. Discover how nonclinical safety studies, evolving regulatory expectations and real-world case examples can help you navigate these challenges with greater confidence.
Meeting ethical & regulatory requirements when using human biological specimens
Building better therapeutic antibodies: the science, progress and problems to solve
Oligonucleotide therapeutics safety considerations across drug development
On-demand Webinars
- Previous
- Next
